METTL3-m6A Promotes FFAR4 Levels in Patients with Endocrine Dysfunctional Osteoporosis Syndrome.
[INTRODUCTION] Endocrine Dysfunctional Osteoporosis Syndrome (EDOS) is a bone disorder characterized by significant changes in bone microstructure leading to degradation and reduced strength, often re
APA
Huang Q, Xu X, Song X (2026). METTL3-m6A Promotes FFAR4 Levels in Patients with Endocrine Dysfunctional Osteoporosis Syndrome.. Combinatorial chemistry & high throughput screening. https://doi.org/10.2174/0113862073379414251110075210
MLA
Huang Q, et al.. "METTL3-m6A Promotes FFAR4 Levels in Patients with Endocrine Dysfunctional Osteoporosis Syndrome.." Combinatorial chemistry & high throughput screening, 2026.
PMID
41830139
Abstract
[INTRODUCTION] Endocrine Dysfunctional Osteoporosis Syndrome (EDOS) is a bone disorder characterized by significant changes in bone microstructure leading to degradation and reduced strength, often resulting in fractures. This research investigates the impact of FFAR4 on individuals suffering from EDOS and elucidates its underlying mechanism.
[METHODS] Samples were gathered from patients diagnosed with EDOS and healthy participants (referred to as "normal") at Taizhou Hospital affiliated with Wenzhou Medical University. Bone Marrow Mesenchymal Stem Cells (BMSCs) and MC3T3-E1 cells were utilized in this investigation. An osteoporosis model was induced in mice through Ovariectomy (OVX).
[RESULTS] Elevated levels of serum mRNA expression of FFAR4 were notably observed in individuals with EDOS. Furthermore, a negative correlation was established between serum mRNA expression of FFAR4 and serum ALP or Run2 levels in EDOS patients. The upregulation of FFAR4 mRNA and protein expressions was also observed in mouse models with EDOS. Inhibition of FFAR4 enhanced bone cell growth within the in vitro model and promoted osteogenic differentiation of BMSCs.
[DISCUSSION] Additionally, FFAR4 inhibition was associated with the onset of osteoporosis in the mouse model of EDOS. The stability of FFAR4 was regulated by METTL3-mediated m6A modification. LPA1 emerged as a critical target for FFAR4 in the EDOS model.
[CONCLUSION] Our study suggests that the FFAR4 exacerbates osteoclast differentiation in the EDOS model through the LPA1 axis. FFAR4 is identified as a facilitator of osteoporosis in the development of EDOS, potentially serving as a diagnostic biomarker and therapeutic target for individuals afflicted with this syndrome.
[METHODS] Samples were gathered from patients diagnosed with EDOS and healthy participants (referred to as "normal") at Taizhou Hospital affiliated with Wenzhou Medical University. Bone Marrow Mesenchymal Stem Cells (BMSCs) and MC3T3-E1 cells were utilized in this investigation. An osteoporosis model was induced in mice through Ovariectomy (OVX).
[RESULTS] Elevated levels of serum mRNA expression of FFAR4 were notably observed in individuals with EDOS. Furthermore, a negative correlation was established between serum mRNA expression of FFAR4 and serum ALP or Run2 levels in EDOS patients. The upregulation of FFAR4 mRNA and protein expressions was also observed in mouse models with EDOS. Inhibition of FFAR4 enhanced bone cell growth within the in vitro model and promoted osteogenic differentiation of BMSCs.
[DISCUSSION] Additionally, FFAR4 inhibition was associated with the onset of osteoporosis in the mouse model of EDOS. The stability of FFAR4 was regulated by METTL3-mediated m6A modification. LPA1 emerged as a critical target for FFAR4 in the EDOS model.
[CONCLUSION] Our study suggests that the FFAR4 exacerbates osteoclast differentiation in the EDOS model through the LPA1 axis. FFAR4 is identified as a facilitator of osteoporosis in the development of EDOS, potentially serving as a diagnostic biomarker and therapeutic target for individuals afflicted with this syndrome.
같은 제1저자의 인용 많은 논문 (5)
- Deep learning for the change-point Cox model with current status data.
- A cognitive divide in active surveillance acceptance persists between surgeons and endocrinologists managing low-risk thyroid cancer.
- MALT1 Knockdown Alleviates Multiorgan Injury and Inflammation Through Inhibiting TAK1/NF-κB Signaling Pathway-Mediated T-Helper 1 and 17 Differentiations in LPS-induced Inflammation.
- Correction: Radiomics reveals the biological basis for non-small cell lung cancer prognostic stratification by reflecting tumor immune microenvironment heterogeneity.
- FILM-Screen: A fully integrated microfluidic platform for point-of-care lung cancer screening via multiplexed mRNA profiling in blood.